Not Tagged
Not Tagged
['import', 'sclc', 'nsclc', 'emd']
io vs ct-io in pts with pd-l1 50%+ nsclc: the fda pooled analysis does not help. similar tails of the curves = same % of long responders. no data on tumor burden, most important factor to select the best strategy! phase iii trial pers e explores prospectively this dilemma #asco22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.